Using 5 administrative claims databases and 3 electronic health databases of more than 2.3 million patients initiating antihypertensive agents, researchers compared clinical endpoints, safety, and adverse effects between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.

Read the Journal Scan